Preclinical Development – Biomolecular
2019 PharmSci 360
Cancer vaccine is a dream for future molecular therapy. However, promising vector career for development of potential vaccines are still under investigation . Repeated lys-ala-leu-ala peptide embedded with DNA-lipid nanoparticles induced boom transgene expression in BMDC and thereby potential antigen presentation were already reported. Here we have constructed plasmid epitope with a MART-1 protein usually expressed in melanoma cancer cell surface and thereby a repeated lys-ala-leu-ala peptide-lipid fabrication was done encapsulating the epitopic plasmid. The encapsulation was done with protamine condenser and DOPE-CHEMS lipid with an average size of 138 nm (potential 37 mV). The nanoparticles were lyophilized using trehalose 100mM. Immunizations were performed in C57Bl/6 mice after reconstitution of lyophilized nanoparticles. The immunized mice were later challenged against B16F10 melanoma tumor cells. After a study of 30 days, cancer cells were halted in immunized mice and our career might be a milestone in cancer vaccines in the days ahead.